Merck and Moderna announced that their personalized cancer vaccine significantly reduced the risk of melanoma recurrence and spread in a Phase 2 trial involving over 1,000 patients. The vaccine is designed to target specific mutations in a patient's tumor, training the immune system to attack cancer cells. The positive results offer new hope for cancer patients and could pave the way for regulatory approval and broader use.
Don't miss out on breaking stories and in-depth articles.
